{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T14:37:05Z","timestamp":1769092625899,"version":"3.49.0"},"reference-count":38,"publisher":"American Society of Tropical Medicine and Hygiene","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,9,3]]},"abstract":"<jats:p>Convergence of geographic regions endemic for human immunodeficiency virus (HIV) and cutaneous leishmaniasis (CL) raise concerns that HIV co-infection may worsen CL burden, complicating already lengthy and costly CL treatments and highlighting a need for newer therapies. We constructed two Markov decision models to quantify impact of HIV on CL and help establish a target product profile for new CL treatments, accounting for co-infection. The HIV co-infection increased lifetime cost per CL case 11\u2013371 times ($1,349\u201345,683) that of HIV-negative individuals ($123) and Brazil's CL burden from $1.6\u201316.0 million to $1.6\u201365.5 million. A new treatment could be a cost saving at \u2264 $254 across several ranges (treatments seeking probabilities, side effect risks, cure rates) and continues to save costs up to $508 across treatment-seeking probabilities with a drug cure rate of \u2265 50%. The HIV co-infection can increase CL burden, suggesting more joint HIV and CL surveillance and control efforts are needed.<\/jats:p>","DOI":"10.4269\/ajtmh.13-0309","type":"journal-article","created":{"date-parts":[[2014,7,8]],"date-time":"2014-07-08T05:00:12Z","timestamp":1404795612000},"page":"520-527","source":"Crossref","is-referenced-by-count":5,"title":["The Impact of Human Immunodeficiency Virus (HIV) Co-Infection on the Economic Burden of Cutaneous Leishmaniasis (CL) in Brazil and Potential Value of New CL Drug Treatments"],"prefix":"10.4269","volume":"91","author":[{"given":"Stephanie D.","family":"Kruchten","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristina M.","family":"Bacon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce Y.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2795","reference":[{"key":"R1","series-title":"Cochrane Database Syst Rev","first-page":"1","article-title":"Interventions for American cutaneous and mucocutaneous leishmaniasis (Review)","author":"Gonzalez","year":"2009"},{"key":"R2","series-title":"Ann Trop Med Parasitol","first-page":"S135","article-title":"Treatment of leishmaniasis in HIV-positive patients","volume":"97","author":"Laguna","year":"2003"},{"key":"R3","series-title":"Ann Trop Med Parasitol","first-page":"17","article-title":"Leishmania\/HIV co-infection in Brazil: an appraisal","volume":"97","author":"Rabello","year":"2003"},{"key":"R4","series-title":"Vaccine","first-page":"480","article-title":"The potential economic value of a cutaneous leishmaniasis vaccine in seven endemic countries in the Americas","volume":"31","author":"Bacon","year":"2012"},{"key":"R5","series-title":"PLoS ONE","first-page":"e35671","article-title":"Leishmaniasis worldwide and global estimates of its incidence","volume":"7","author":"Alvar","year":"2012"},{"key":"R6","series-title":"Clin Microbiol Rev","first-page":"334","article-title":"The relationship between leishmaniasis and AIDS: the second 10 years","volume":"21","author":"Alvar","year":"2008"},{"key":"R7","series-title":"Am J Trop Med Hyg","first-page":"524","article-title":"American tegumentary leishmaniasis and HIV-AIDS association in a tertiary care center in the Brazilian Amazon","volume":"85","author":"Guerra","year":"2011"},{"key":"R8","series-title":"Am J Trop Med Hyg","first-page":"847","article-title":"Phlebotomine vector ecology in the domestic transmission of American cutaneous leishmaniasis in Chaparral, Colombia","volume":"85","author":"Ferro","year":"2011"},{"key":"R9","series-title":"Am J Trop Med Hyg","first-page":"577","article-title":"Comparison of generic to branded pentavalent antimony for treatment of new world cutaneous leishmaniasis","volume":"71","author":"Soto","year":"2004"},{"key":"R10","series-title":"Lancet","first-page":"1191","article-title":"Leishmaniasis","volume":"354","author":"Herwaldt","year":"1999"},{"key":"R11","series-title":"Information on the Epidemiology and Control of the Leishmaniases by Country or Territory","first-page":"47","author":"Desjeux","year":"1991"},{"key":"R12","series-title":"Int J Dermatol","first-page":"109","article-title":"Treatment of new world cutaneous leishmaniasis: a systematic review with a meta-analysis","volume":"47","author":"Tuon","year":"2008"},{"key":"R13","series-title":"Am J Trop Med Hyg","first-page":"266","article-title":"Treatment of mucosal leishmaniasis in Latin America: systematic review","volume":"77","author":"Amato","year":"2007"},{"key":"R14","series-title":"Br J Dermatol","first-page":"1328","article-title":"Diffuse cutaneous leishmaniasis responds to miltefosine but then relapses","volume":"156","author":"Zerpa","year":"2007"},{"key":"R15","series-title":"Control of Leishmaniases","article-title":"Report of a meeting of the WHO Expert Committee on the control of leishmaniases, Geneva, 22\u201326 March 2010","author":"WHO","year":"2010"},{"key":"R16","series-title":"J Eur Acad Dermatol","first-page":"218","article-title":"American cutaneous leishmaniasis associated with HIV infection: report of four cases","volume":"10","author":"Mattos","year":"1998"},{"key":"R17","series-title":"Expert Rev Anti Infect Ther","first-page":"177","article-title":"Miltefosine: oral treatment of leishmaniasis","volume":"4","author":"Soto","year":"2006"},{"key":"R18","first-page":"21","article-title":"Application for inclusion of Miltefosine on WHO Model List of Essential Medicines","author":"Vinson","year":"2010"},{"key":"R19","series-title":"The HIV Drug Book: Revised and Updated","author":"Project Inform","year":"1998"},{"key":"R20","series-title":"Clin Infect Dis","first-page":"334","article-title":"Amphotericin B use in a community hospital with special emphasis on side effects","volume":"26","author":"Patthak","year":"1998"},{"key":"R21","series-title":"Trop Med Int Health","first-page":"1540","article-title":"Short communication: the cost-effectiveness of cutaneous leishmaniasis patient management during an epidemic in Chaparral, Columbia in 2004","volume":"12","author":"Vega","year":"2007"},{"key":"R22","series-title":"WHO-CHOICE: Choosing Interventions that are Cost Effective","author":"WHO","year":"2008"},{"key":"R23","series-title":"J Infect Dis","first-page":"1829","article-title":"Disseminated leishmaniasis: a new and emerging form of leishmaniasis observed in northeastern Brazil","volume":"186","author":"Turetz","year":"2002"},{"key":"R24","series-title":"Cost-effectiveness in Health and Medicine","first-page":"91","volume":"2","author":"Shepard","year":"1999"},{"key":"R25","series-title":"Global Health Observatory Data Repository, Life Expectancy: Life Tables Brazil","author":"World Health Organization","year":"2013"},{"key":"R26","series-title":"Lancet","first-page":"1561","article-title":"Advances in leishmaniasis","volume":"366","author":"Murray","year":"2005"},{"key":"R27","series-title":"Dermatol Ther","first-page":"491","article-title":"Cutaneous and mucocutaneous leishmaniasis","volume":"22","author":"David","year":"2009"},{"key":"R28","series-title":"Int J Technol Assess","first-page":"126","article-title":"Dialysis care, cardiovascular disease, and costs in end-stage renal disease in Brazil","volume":"23","author":"Sesso","year":"2007"},{"key":"R29","series-title":"Trans R Soc Trop Med Hyg","first-page":"159","article-title":"Visceral leishmaniasis and HIV-1 co-infection in southern France","volume":"89","author":"Rosenthal","year":"1995"},{"key":"R30","series-title":"AIDS","first-page":"1499","article-title":"Visceral leishmaniasis in HIV-1-infected individuals: a common opportunistic infection in Spain?","volume":"6","author":"Medrano","year":"1992"},{"key":"R31","series-title":"Ann Trop Med Parasitol","first-page":"S3","article-title":"Leishmania\/HIV co-infections: epidemiology in Europe","volume":"97","author":"Desjeax","year":"2003"},{"key":"R32","series-title":"Am Fam Physician","first-page":"1455","article-title":"Cutaneous leishmaniasis: recognition and treatment","volume":"69","author":"Markle","year":"2004"},{"key":"R33","series-title":"Mol Biol Int","first-page":"23","article-title":"Use of antimony in the treatment of leishmaniasis: current status and future directions","volume":"2011","author":"Haldar","year":"2011"},{"key":"R34","series-title":"World Bank Data: Health expenditures, total (% of GDP)","author":"The World Bank","year":"2013"},{"key":"R35","series-title":"Disease Control Priorities in Developing Countries: The World Bank","author":"Jamison","year":"2006"},{"key":"R36","series-title":"Clin Infect Dis","first-page":"1139","article-title":"Digital decision making: computer models and antibiotic prescribing in the twenty-first century","volume":"46","author":"Lee","year":"2008"},{"key":"R37","series-title":"PLoS Med","first-page":"e99","article-title":"Screening the United States blood supply for West Nile Virus: a question of blood, dollars, and sense","volume":"3","author":"Lee","year":"2006"},{"key":"R38","series-title":"Drugs","first-page":"1009","article-title":"Practical guide for the treatment of leishmaniasis","volume":"56","author":"Davidson","year":"1998"}],"container-title":["The American Society of Tropical Medicine and Hygiene"],"original-title":[],"link":[{"URL":"https:\/\/www.ajtmh.org\/view\/journals\/tpmd\/91\/3\/article-p520.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ajtmh.org\/downloadpdf\/journals\/tpmd\/91\/3\/article-p520.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/www.ajtmh.org\/downloadpdf\/journals\/tpmd\/91\/3\/article-p520.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T21:16:24Z","timestamp":1723065384000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ajtmh.org\/view\/journals\/tpmd\/91\/3\/article-p520.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,3]]},"references-count":38,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.4269\/ajtmh.13-0309","relation":{},"ISSN":["0002-9637","1476-1645"],"issn-type":[{"value":"0002-9637","type":"print"},{"value":"1476-1645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,3]]}}}